Akebia Therapeutics, Inc. Common Stock AKBA
i
Market dataready · fetched 2026-11-04T03:50:03.233Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T22:48:22.02626853Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-04T03:50:02.827207+00:00
Akebia Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 0.59 | 231.0% | 32.4% | |||
| 25Δ | 0.66 | 256.5% | 30.5% | |||
| 30Δ | 0.73 | 281.9% | 28.5% | |||
| 35Δ | 0.80 | 307.3% | 26.6% | |||
| 40Δ | 0.87 | 332.8% | 24.7% | |||
| 45Δ | 0.94 | 358.2% | 22.8% | |||
| 50Δ | 1.02 | 377.8% | 20.8% | |||
| 55Δ | 1.12 | 368.4% | 18.1% | |||
| 60Δ | 1.21 | 358.9% | 15.4% | |||
| 65Δ | 0.65 | 220.2% | 16.4% | 1.31 | 349.5% | 12.6% |
| 70Δ | 0.61 | 227.9% | 13.7% | 1.41 | 340.1% | 9.9% |
| 75Δ | 0.57 | 235.6% | 10.9% | 1.62 | 348.9% | 7.5% |
| 80Δ | 0.53 | 243.3% | 8.2% | 2.38 | 415.7% | 6.2% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.59
- IV
- 231.0%
- B/E move
- 32.4%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.66
- IV
- 256.5%
- B/E move
- 30.5%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.73
- IV
- 281.9%
- B/E move
- 28.5%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.80
- IV
- 307.3%
- B/E move
- 26.6%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.87
- IV
- 332.8%
- B/E move
- 24.7%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.94
- IV
- 358.2%
- B/E move
- 22.8%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.02
- IV
- 377.8%
- B/E move
- 20.8%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.12
- IV
- 368.4%
- B/E move
- 18.1%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.21
- IV
- 358.9%
- B/E move
- 15.4%
65Δ
- Pseudo strike
- 0.65
- IV
- 220.2%
- B/E move
- 16.4%
- Pseudo strike
- 1.31
- IV
- 349.5%
- B/E move
- 12.6%
70Δ
- Pseudo strike
- 0.61
- IV
- 227.9%
- B/E move
- 13.7%
- Pseudo strike
- 1.41
- IV
- 340.1%
- B/E move
- 9.9%
75Δ
- Pseudo strike
- 0.57
- IV
- 235.6%
- B/E move
- 10.9%
- Pseudo strike
- 1.62
- IV
- 348.9%
- B/E move
- 7.5%
80Δ
- Pseudo strike
- 0.53
- IV
- 243.3%
- B/E move
- 8.2%
- Pseudo strike
- 2.38
- IV
- 415.7%
- B/E move
- 6.2%
Options history
Table
| Date | IV (%) |
|---|---|
| 193.60% | |
| 220.33% | |
| 182.58% | |
| 177.59% | |
| 184.48% | |
| 200.06% | |
| 240.47% | |
| 137.77% | |
| 226.26% | |
| 221.94% | |
| 259.07% | |
| 233.94% | |
| 251.56% | |
| 270.20% |
Drug Manufacturers - Specialty & Generic
ALKS
Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in…
More →AMLX
Amylyx Pharmaceuticals Inc (AMLX) is an innovative biopharmaceutical company at the forefront of developing transformative therapies for neurodegenerative diseases, particularly…
More →AMPH
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal…
More →AMRX
Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic…
More →ANIK
Description unavailable
More →ANIP
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets brand-name and generic prescription pharmaceuticals in the United States and…
More →